Key Points
- Axon CFO Brittany Bagley sold 2,000 shares on Dec. 11 at an average price of $580 for $1.16M, leaving her with 103,501 shares (a 1.90% reduction) valued at about $60.03M.
- Bagley has repeatedly sold shares this year — including 2,500 at $610 (Nov. 10), 5,000 at $713.88 (Sept. 29) and 870 at $773.25 (Sept. 15) — indicating a sustained pattern of insider selling.
- Axon stock opened at $564.28 (down 2.9%), trades in a 52‑week range of $469.24–$885.91, carries a high P/E (~179), reported 30.6% revenue growth but an EPS miss last quarter, and has a consensus "Moderate Buy" analyst rating with an average target of about $815.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CFO Brittany Bagley sold 2,000 shares of the company's stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares of the company's stock, valued at $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Brittany Bagley also recently made the following trade(s):
- On Monday, November 10th, Brittany Bagley sold 2,500 shares of Axon Enterprise stock. The shares were sold at an average price of $610.00, for a total value of $1,525,000.00.
- On Monday, September 29th, Brittany Bagley sold 5,000 shares of Axon Enterprise stock. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00.
- On Monday, September 15th, Brittany Bagley sold 870 shares of Axon Enterprise stock. The stock was sold at an average price of $773.25, for a total value of $672,727.50.
Axon Enterprise Stock Down 2.9%
NASDAQ AXON opened at $564.28 on Friday. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $44.53 billion, a P/E ratio of 178.57, a price-to-earnings-growth ratio of 133.45 and a beta of 1.40. The stock's 50-day moving average price is $623.94 and its 200-day moving average price is $714.38.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million during the quarter, compared to analysts' expectations of $704.83 million. During the same period in the prior year, the company posted $1.45 earnings per share. The company's revenue was up 30.6% compared to the same quarter last year. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on AXON. UBS Group reduced their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a "neutral" rating for the company in a research note on Wednesday, November 5th. JMP Securities reiterated a "market outperform" rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday, September 29th. Piper Sandler decreased their price target on Axon Enterprise from $893.00 to $753.00 and set an "overweight" rating on the stock in a report on Wednesday, November 5th. Barclays dropped their price objective on Axon Enterprise from $861.00 to $702.00 and set an "overweight" rating for the company in a research note on Thursday, November 6th. Finally, Zacks Research cut Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 2nd. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average price target of $815.00.
Get Our Latest Research Report on AXON
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in AXON. Vestor Capital LLC lifted its position in shares of Axon Enterprise by 438,636.3% in the second quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company's stock worth $690,170,000 after buying an additional 833,409 shares in the last quarter. Norges Bank purchased a new position in Axon Enterprise during the 2nd quarter valued at approximately $637,806,000. Vanguard Group Inc. increased its stake in Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company's stock worth $6,684,217,000 after acquiring an additional 376,904 shares during the last quarter. Jennison Associates LLC increased its stake in Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company's stock worth $677,412,000 after acquiring an additional 330,213 shares during the last quarter. Finally, McElhenny Sheffield Capital Management LLC purchased a new stake in shares of Axon Enterprise during the 2nd quarter worth approximately $255,833,000. Institutional investors own 79.08% of the company's stock.
About Axon Enterprise
(
Get Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
